| Literature DB >> 30007230 |
Jiahuan Zou1, Mengwei Zhuang1, Xiaopeng Yu1, Na Li1, Rudi Mao1, Zhida Wang1, Jianing Wang1, Xiaoyan Wang1, Huaiyu Zhou2, Lining Zhang1, Yongyu Shi3.
Abstract
The effectiveness of immunotherapy targeting the immune checkpoint PD-L1/PD-1 pathway highlights importance of elucidating the regulatory mechanisms of PD-L1 expression in cancer cells. Previous studies demonstrate that oncogene MYC up-regulates PD-L1 expression in lymphomas. In the present study, we investigated the regulatory role of MYC in the PD-L1 expression induced by IFN-γ in HCC cells. Unexpectedly, knockdown of MYC expression using siRNA assay increased the inducible expression of PD-L1 both at mRNA and protein levels. Mechanistically, the inhibition of MYC elevated expression of STAT1, a critical component of IFN-γ signaling pathway, leading to the elevation of PD-L1 expression in HCC cells exposed to IFN-γ. These results suggest that MYC may down-regulate PD-L1 expression in the context of HCC. This study implicates that a combination therapy targeting MYC function and PD-L1/PD-1 pathway might be effective for treatment of HCC.Entities:
Keywords: B7-H1; CD274; Hepatocelluar carcinomas; Immune checkpoints; MYC; PD-L1
Mesh:
Substances:
Year: 2018 PMID: 30007230 DOI: 10.1016/j.molimm.2018.07.006
Source DB: PubMed Journal: Mol Immunol ISSN: 0161-5890 Impact factor: 4.407